Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: The carvedilol-metoprolol study

Journal of Hypertension

Volumn 14, Issue 4, 1996, Pages 489-494

  Jacob, Stephan ^a,b,d   Rett, Kristian ^b   Wicklmayr, Matthias ^b   Agrawal, Bhuwnesh ^c   Augustin, Hans J ^a,b   Dietze, Günther J ^b  

^a Stadtklinik ^*  (Germany)

^b Max Grundig Clinic   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d Department of Internal Medicine   (Germany)

Author keywords

Antihypertensive treatment; Atherogenic risk profile; Carvedilol; Insulin sensitivity; Metabolic syndrome; Metoprolol

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN; LIPID; METOPROLOL; TRIACYLGLYCEROL;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SELECTIVITY; ELECTROLYTE BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART RATE; HUMAN; HYPERINSULINEMIA; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC CLEARANCE RATE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029998396     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Dieterle P, Fehm H, Ströter W, Henner H, Bottermann J, Schwarz K: Asymptomatischer Diabetes mellitus bei normalgewichtigen Hypertonikern. Dtsch Med Wochenschr 1967, 92:2376-2382.
2. Ferrannini E, Buzzigoli G, Bonadona R, Giorico MA, Oleggini M, Graziadei L, et al.: Insulin resistance in essential hypertension. N Engl J Med 1987, 317:350-357.
3. Morris AD, Petrie JR, Connell JMC: Insulin and hypertension. J Hypertens 1994, 12:633-642.
4. Pollare T, Lithell HO, Berne C: Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990, 39:167-174.
5. Natali A, Santoro D, Palombo C, Cerri M, Ghione S, Feranninni E: Impaired insulin action on skeletal muscle metabolism in essential hypertension. Hypertension 1991, 17:170-178.
6. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:595-1607.
7. De Fronzo RA, Ferrannini E: Insulin resistance a multifaceted syndrome responsible for NIDDM, obesity, hypertension, and dyslipidemia. Diabetes Care 1991, 14:173-177.
8. Bengstsson C, Blohme G, Lapidus L, Lindquist O, Lundgren H, Nyström E, et al.: Do antihypertensive drugs precipitate diabetes? BMJ 1984, 289:1495-1497.
9. Skarfors ET, Lithell HO, Selinus I, Aberg H: Do antihypertensive drugs precipitate diabetes in predisposed men? BMJ 1989, 298:1147-1152.
10. Lithell HO: Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991, 14:203-209.
11. Gambardella S, Frontoni S, Pellegrinotti M, Testa G, Spallone V, Menzinger G: Carbohydrate metabolism in hypertension: influence of treatment. J Cardiovasc Pharmacol 1993, 22 (suppl 6): S87-S97.
12. Pollare T, Lithell HO, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989, 321:868-873.
13. Pollare T, Lithell HO, Selinus I, Berne C: Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989, 298:1152-1157.
14. Pollare T, Lithell H, Mörlin C, Präntare H, Hvarfner A, Ljunghall S: Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens 1989, 7:551-559.
15. 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 1994, 43:455-461.
16. Pollare T, Lithell HO, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988, 31:415-420.
17. Huupponen R, Lehtonen A, Vähätalo M: Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. Eur J Clin Pharmacol 1992, 43:365-368.
18. Jauch KW, Hartl W, Günther B, Wicklmayr M, Rett K, Dietze G: Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Zur J Clin Invest 1987, 17:448-454.
19. Rett K, Lotz N, Wicklmayr M, Fink E, Jauch KW, Günther B, et al.: Verbesserte insulinwirkung durch ACE-Hemmung beim Typ-II-Diabetiker. Dtsch Med Wochenschr 1988, 113:243-249.
20. Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, Erberlein KA, et al.: Blood pressure, stroke and coronary heart disease. Part 2. Short term reductions in blood pressure: overview of randomised drug trial in their epidemiological context. Lancet 1990, 335:827-838.
21. Black HR: The coronary artery disease paradox: the role of hyperinsulinemia and insulin resistance and implications for therapy. J Cardiovasc Pharmacol 1990, 15 (suppl 5): S26-S38.
22. Black HR: Metabolic considerations in the choice of therapy for the patient with hypertension. Am Heart J 1991, 121:707-715.
23. Rosman J, Weidmann P, Ferrari P: Antihypertensive drugs and serum lipoprotein levels. J Drug Dev 1990, 3 (suppl 1):129-139.
24. Weber MA: Hypertension with concomitant conditions: the changing role of β-adrenoreceptor blockade. Am Heart J 1991; 121:716-723.
25. Eggertsen R, Sivertsson R, Andren L, Hansson L: Hemodynamic effects of carvedilol, a new beta-adrenoreceptor blocker and precapillary vasodilator, in essential hypertension. J Hypertens 1984, 2:529-534.
26. Eggertsen R, Sivertsson R, Andren L, Hansson L: Acute and long term hemodynamic effects of carvedilol, a combined beta-adrenoreceptor blocking and pre-capillary vasodilating agent, in hypertensive patients. J Cardiovasc Pharmacol 1987, 10: S76-S80.
27. Sponer G, Bartsch W, Strein K, Müller-Beckmann B, Böhn E: Pharmacological profile of carvedilol as a betablocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol 1987, 9:317-327.
28. Hauf-Zachariou U, Widmann L, Zulsdorf B, Hennig M, Lang PD: A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidemia. Eur J Clin Pharmacol 1993, 45:95-100.
29. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979, 28:1039-1057.
30. De Fronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237: E214-E223.
31. Rizza RA, Mandarion LJ, Gerich JE: Dose-response characteristics for the effects of insulin production and utilization of glucose in man. Am J Physiol 1981, 240: E630-E639.
32. Jacob S, Warth B, Thies R, Ouredniceck P, vErckelens C, Augustin HJ, et al.: Milde Hypertriglyzeridämie bei Hypertonie-Nur die Spitze eines Eisberges? Nieren- und Hochdruckkrankheiten 1993, 7:335-338.
33. Malminiemi K, Lahtela JT, Huupponen R: Effect of celiprolol on insulin sensitivity and glucose tolerance in dyslipidemic hypertension. Int J Clin Pharmacol Ther 1995, 32:156-163.
34. Swislocki ALM: Impaired insulin clearance in essential hypertension. J Hum Hypertens 1994, 8:185-190.
35. Lithell H: Metabolic effects of antihypertensive drugs interacting with the sympathetic nervous system. Eur Heart J 1992, 13 (suppl A):53-57.
36. Lithell H, Pollare T, Vessby B: Lipoprotein lipase activity in skeletal muscle is related to insulin sensitivity. Arterioscler Thromb 1991, 11:1192-1203.
37. Wolinsky H: The effects of beta-adrenergic blocking agents on blood lipid levels. Clin Cardiol 1987, 10:561-566.
38. Rabkin SW: Mechanisms of action of adrenergic receptor blockers on lipids during antihypertensive drug treatment. J Clin Pharmacol 1993, 33:286-291.
39. Baron AD, Brechtel-Hook G, Johnson A, Hardin D: Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension 1993, 21:129-135.
40. Lind L, Lithell H: Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia, and hyperinsulinemia. Am Heart J 1993, 125:1494-1497.
41. Rocchini AP, Moorehead C, Katch V, Key J, Finta KM: Forearm resistance vessel abnormalities and insulin resistance in obese adolescents. Hypertension 1992, 19:615-620.
42. Lund-Johansen P, Omvik P, Nordrehaug JE: Long-term hemodynamic effects of antihypertensive treatment. Clin Invest 1992, 70: S58-S64.
43. Böhmeke T, Weber K, van der Does R, Nöcker B, Ricken D: Akute und subchronische kardiovaskuläre Effekte des vasodilatierenden Betablockers Carvedilol im Vergleich zu Metoprolol in der Therapie der arteriellen Hypertonie. (Antihypertensive therapy with the vasodilating betablocker carvedilol: comparison of acute and subchronic cardiovascular effects with metoprolol.) Herz Kreislauf 1994, 26:22-26.
44. Kodama J, Katayama S, Tanaka K, Itabashi A, Kawazu S, Ishii J: Effect of captopril on glucose concentration. Possible role of augmented postprandial forearm blood flow. Diabetes Care 1990, 13:1109-1111.